Aurinia Pharmaceuticals (NASDAQ:AUPH) Shares Gap Up to $5.13
Aurinia Pharmaceuticals (NASDAQ:AUPH) Shares Gap Up to $5.13
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Rating) (TSE:AUP) shares gapped up before the market opened on Thursday . The stock had previously closed at $5.13, but opened at $5.33. Aurinia Pharmaceuticals shares last traded at $5.19, with a volume of 8,387 shares traded.
金色醫藥股份有限公司(納斯達克代碼：AUPH-GET評級)(東京證券交易所代碼：AUP)的股票在週四開盤前大幅上漲。該股此前收盤報5.13美元，開盤報5.33美元。Aurinia PharmPharmticals的股票最新報5.19美元，成交量為8,387股。
Analyst Ratings Changes
分析師評級發生變化
A number of analysts have commented on the stock. Royal Bank of Canada cut their price target on shares of Aurinia Pharmaceuticals from $18.00 to $10.00 and set an "outperform" rating for the company in a research note on Friday, November 4th. HC Wainwright cut their price target on shares of Aurinia Pharmaceuticals from $26.00 to $14.00 and set a "buy" rating for the company in a research note on Monday, November 7th. StockNews.com assumed coverage on shares of Aurinia Pharmaceuticals in a research note on Wednesday, October 12th. They issued a "hold" rating for the company. Oppenheimer cut shares of Aurinia Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research note on Friday, November 4th. Finally, SVB Leerink cut their price target on shares of Aurinia Pharmaceuticals from $17.00 to $12.00 and set an "outperform" rating for the company in a research note on Friday, November 4th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Aurinia Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $12.25.
一些分析師對該股發表了評論。11月4日，週五，加拿大皇家銀行在一份研究報告中將金色醫藥的目標價從18.00美元下調至10.00美元，併為該公司設定了“跑贏大盤”的評級。11月7日，HC Wainwright在一份研究報告中將aurinia PharmPharmticals的股票目標價從26.00美元下調至14.00美元，併為該公司設定了“買入”評級。StockNews.com在10月12日星期三的一份研究報告中對aurinia PharmPharmticals的股票進行了報道。他們對該公司的評級為“持有”。奧本海默在11月4日星期五的一份研究報告中將aurinia PharmPharmticals的股票評級從“跑贏大盤”下調至“市場表現”。最後，SVB Leerink在11月4日(星期五)的一份研究報告中將aurinia PharmPharmticals的股票目標價從17.00美元下調至12.00美元，併為該公司設定了“表現優於大盤”的評級。兩名股票研究分析師對該股的評級為持有，五名分析師對該股的評級為買入。根據MarketBeat的數據，aurinia PharmPharmticals的共識評級為“中等買入”，共識目標價為12.25美元。
Aurinia Pharmaceuticals Price Performance
金銀花葯品價格表現
The company has a market capitalization of $724.76 million, a P/E ratio of -6.14 and a beta of 0.82. The company's 50-day moving average price is $6.43 and its two-hundred day moving average price is $8.51.
該公司市值為7.2476億美元，市盈率為-6.14，貝塔係數為0.82。該公司的50日移動均線價格為6.43美元，200日移動均線價格為8.51美元。
Hedge Funds Weigh In On Aurinia Pharmaceuticals
對衝基金買入Auinia製藥公司
About Aurinia Pharmaceuticals
金色製藥公司簡介
(Get Rating)
(獲取評級)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.
Auinia製藥公司是一家商業階段的生物製藥公司，專注於開發治療方法並將其商業化，以治療在美國和國際上未得到滿足的醫療需求的各種疾病。該公司提供LUPKYNIS用於治療成人活動性狼瘡性腎炎。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Aurinia Pharmaceuticals (AUPH)
- Why CSL Ltd Stock Could Be Worth a Look
- MarketBeat: Week in Review 11/28 – 12/02
- Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
- Institutions Are Buying Ambarella, Should You?
- Can ZIM Defy Broad Downturn In The Container Shipping Industry?
- 免費獲取StockNews.com關於金銀花製藥的研究報告(AUPH)
- 為什麼CSL有限公司的股票值得一看
- MarketBeat：回顧一週11/28-12/02
- Okta Inc.慶祝收益節節攀升，但他們能持續這種提振嗎？
- 機構正在購買安巴雷拉，你應該嗎？
- ZIM能否抵禦集裝箱航運業的普遍低迷？
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《金色醫藥日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對aurinia PharmPharmticals和相關公司的最新新聞和分析師評級的每日摘要。